264 related articles for article (PubMed ID: 32497081)
21. The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors.
Kannan S; Partridge AW; Lane DP; Verma CS
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795143
[TBL] [Abstract][Full Text] [Related]
22. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
[TBL] [Abstract][Full Text] [Related]
23. mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction.
Shiheido H; Takashima H; Doi N; Yanagawa H
PLoS One; 2011 Mar; 6(3):e17898. PubMed ID: 21423613
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
25. Molecular recognition of p53 and MDM2 by USP7/HAUSP.
Sheng Y; Saridakis V; Sarkari F; Duan S; Wu T; Arrowsmith CH; Frappier L
Nat Struct Mol Biol; 2006 Mar; 13(3):285-91. PubMed ID: 16474402
[TBL] [Abstract][Full Text] [Related]
26. Anticancer Effects of a New SIRT Inhibitor, MHY2256, against Human Breast Cancer MCF-7 Cells via Regulation of MDM2-p53 Binding.
Park EY; Woo Y; Kim SJ; Kim DH; Lee EK; De U; Kim KS; Lee J; Jung JH; Ha KT; Choi WS; Kim IS; Lee BM; Yoon S; Moon HR; Kim HS
Int J Biol Sci; 2016; 12(12):1555-1567. PubMed ID: 27994519
[TBL] [Abstract][Full Text] [Related]
27. Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding.
Dastidar SG; Lane DP; Verma CS
Cell Cycle; 2012 Jun; 11(12):2239-47. PubMed ID: 22617389
[TBL] [Abstract][Full Text] [Related]
28. The C terminus of p53 binds the N-terminal domain of MDM2.
Poyurovsky MV; Katz C; Laptenko O; Beckerman R; Lokshin M; Ahn J; Byeon IJ; Gabizon R; Mattia M; Zupnick A; Brown LM; Friedler A; Prives C
Nat Struct Mol Biol; 2010 Aug; 17(8):982-9. PubMed ID: 20639885
[TBL] [Abstract][Full Text] [Related]
29. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
30. SMAR1 forms a ternary complex with p53-MDM2 and negatively regulates p53-mediated transcription.
Pavithra L; Mukherjee S; Sreenath K; Kar S; Sakaguchi K; Roy S; Chattopadhyay S
J Mol Biol; 2009 May; 388(4):691-702. PubMed ID: 19303885
[TBL] [Abstract][Full Text] [Related]
31. Domain analysis of Ras-association domain family member 6 upon interaction with MDM2.
Sarkar A; Iwasa H; Hossain S; Xu X; Sawada T; Shimizu T; Maruyama J; Arimoto-Matsuzaki K; Hata Y
FEBS Lett; 2017 Jan; 591(2):260-272. PubMed ID: 28054709
[TBL] [Abstract][Full Text] [Related]
32. Posttranslational modifications affect the interaction of S100 proteins with tumor suppressor p53.
van Dieck J; Teufel DP; Jaulent AM; Fernandez-Fernandez MR; Rutherford TJ; Wyslouch-Cieszynska A; Fersht AR
J Mol Biol; 2009 Dec; 394(5):922-30. PubMed ID: 19819244
[TBL] [Abstract][Full Text] [Related]
33. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.
Ma J; Martin JD; Zhang H; Auger KR; Ho TF; Kirkpatrick RB; Grooms MH; Johanson KO; Tummino PJ; Copeland RA; Lai Z
Biochemistry; 2006 Aug; 45(30):9238-45. PubMed ID: 16866370
[TBL] [Abstract][Full Text] [Related]
34. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
35. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
[TBL] [Abstract][Full Text] [Related]
36. Structure of the stapled p53 peptide bound to Mdm2.
Baek S; Kutchukian PS; Verdine GL; Huber R; Holak TA; Lee KW; Popowicz GM
J Am Chem Soc; 2012 Jan; 134(1):103-6. PubMed ID: 22148351
[TBL] [Abstract][Full Text] [Related]
37. Bridging Microscopic and Macroscopic Mechanisms of p53-MDM2 Binding with Kinetic Network Models.
Zhou G; Pantelopulos GA; Mukherjee S; Voelz VA
Biophys J; 2017 Aug; 113(4):785-793. PubMed ID: 28834715
[TBL] [Abstract][Full Text] [Related]
38. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H
Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135
[TBL] [Abstract][Full Text] [Related]
39. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
Mrkvová Z; Uldrijan S; Pombinho A; Bartůněk P; Slaninová I
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181622
[TBL] [Abstract][Full Text] [Related]
40. Role of the C-terminal extension in the interaction of S100A1 with GFAP, tubulin, the S100A1- and S100B-inhibitory peptide, TRTK-12, and a peptide derived from p53, and the S100A1 inhibitory effect on GFAP polymerization.
Garbuglia M; Verzini M; Rustandi RR; Osterloh D; Weber DJ; Gerke V; Donato R
Biochem Biophys Res Commun; 1999 Jan; 254(1):36-41. PubMed ID: 9920729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]